Tissue Regenix makes appointment to Cardiac team

RNS Number : 1927J

Tissue Regenix Group PLC

02 August 2012

 

For Immediate Release: 2 August 2012

Tissue Regenix makes senior appointment to Cardiac team

York, 2 August 2012 - Tissue Regenix Group plc ('Tissue Regenix'), the regenerative medical devices company has appointed Andrea Rausch as Business Development Manager in its Cardiac team.  The appointment follows the Company's successful £25 million fundraising in December 2011, which is enabling Tissue Regenix to continue its planned expansion.

Andrea joins Tissue Regenix from Sorin Group ('Sorin'), a global medical device company and a leader in the development of medical technologies for cardiac surgery and for the treatment of cardiac rhythm disorders.  For two years, she was Global Marketing Manager at Sorin of the Perceval Programme, a new treatment option for aortic valve disease, having been Business Line Leader and Strategic Sales and Marketing Manager of the Heart Valves team in Germany for five years before that.  Prior to this, she was with Edwards Lifesciences Germany as Area Manager, Heart Valves and Rings and with Krauth Medical KG.

Antony Odell, Managing Director, Tissue Regenix said, "We are delighted that Andrea has joined the Cardiac team at Tissue Regenix as she brings with her considerable experience of this field of medicine.  Since our successful fundraising in December we have defied the wider economic situation and continued to grow the business.  Indeed, our aim is to create up to 20 more high quality medical technology jobs in Yorkshire as part of our planto become a significant global player in regenerative medicine."

Tissue Regenix, which was incorporated in May 2006 to commercialise the academic research of Professor Eileen Ingham and Professor John Fisher from the University of Leeds in the field of tissue decellularisation, is currently also working with other leading academics in the field including Professor Francisco da Costa of the Pontifical University of Parana, Brazil.

The Company is currently developing a porcine heart valve product and is seeking regulatory approval for a decellularised version of an existing bioprosthetic heart valve.  Its dCELL® Vascular Patch provides a highly biocompatible patch for peripheral vascular reconstruction that supports infiltration of the patient's own cells allowing host tissue regeneration.

The dCELL® is a process which removes cells and other components from human and animal tissue allowing it to be used without anti-rejection drugs to replace worn out or diseased body parts.  Tissue Regenix is developing further applications of its dCELL® technology platform, for example, by progressing an dialysis graft for patients with kidney disease into the clinic, which, it is hoped, will mitigate some of the associated risks and reduce the cost of expensive dialysis.

-Ends-

For further information:

Alistair Kellie / Andrew Adie / Martin Greig

Newgate Communications

Tel: [phone]

About Tissue Regenix

Tissue Regenix, (AIM:TRX) the regenerative medical devices company , was incorporated in May 2006 to commercialise the academic research of Professor Eileen Ingham and Professor John Fisher from the University of Leeds in the field of tissue decellularisation.

The dCELL® Vascular Patch provides a highly biocompatible patch for peripheral vascular reconstruction that supports infiltration of the patient's own cells allowing host tissue regeneration.

The dCELL® Vascular Patch is manufactured from porcine pericardium using the proprietary dCELL® process. The dCELL® process removes cellular material from tissues while maintaining the structural and biomechanical properties. This results in an acellular, immunocompatible and immediately functional material.

The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.

 

END

 

 

NRAUGUAPRUPPGWP